<DOC>
	<DOCNO>NCT00733551</DOCNO>
	<brief_summary>This study evaluate safety , tolerability exposure repeat escalate oral dos GSK962040 .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability Pharmacokinetics Repeat Oral Doses GSK962040 Administered Healthy Adult Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Motilin</mesh_term>
	<criteria>Healthy determine physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . In case , liver function test must strictly within normal range screening . Male female 18 55 year age , inclusive . Nonsmoker least 6 month base smoke history . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/mL confirmatory . Childbearing potential agrees use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception least 4 day follow last dose study medication . Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication least 4 day last dose study medication . Body weight &gt; 50 kg BMI within range 18.5 29.9 kg/m2 ( inclusive ) . QTcB QTcF &lt; 450 msec QTc &lt; 480msec subject Bundle Branch Block base single average QTc value triplicate value obtain brief recording period . Normal physical examination ( physical exam demonstrate evidence clinically active disease physical mental impairment ) . A subject clinical abnormality may include Principal Investigator physician designee considers abnormality introduce additional risk factor interfere study procedure . Consultation GSK medical monitor require subject may include . Capable give write informed consent , include compliance requirement restriction list consent form . Subjects negative Helicobacter pylorus status receive eradication within last calendar year . Exclusion Inclusion : History presence clinically significant metabolic condition , gastrointestinal ( include pass &gt; 3 stools/ day &lt; 3 stools/week ) condition endocrinological condition . History presence clinically significant gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . History major gastrointestinal surgical procedure within last 10 year . History cholecystectomy biliary tract disease . History presence thyroid dysfunction ( NOTE : subject abnormal TSH screening/baseline hypothyroidism stable dose thyroid replacement therapy eligible ) . A history presence recreational drug abuse dependence current abuse evidence positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . History regular alcohol consumption within 6 month study define : An average weekly intake great 21 unit average daily intake great 3 unit ( male ) , defined average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent approximately halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test ( first urine day ) screen prior dosing . Lactating pregnant female . Unwillingness inability follow procedure outline protocol . For male volunteer : An unwillingness male subject comply contraception requirement list protocol , time first dose study medication least 4 day follow administration last dose study medication . History current lactose intolerance . Subjects recruit for/participating Cohorts 25 screen subject exhibit rapid gastric empty rate exclude , define reference range baseline gastric empty rate ( t1/2b ) observe cohort 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>motilin</keyword>
	<keyword>gastric empty</keyword>
	<keyword>GSK962040</keyword>
	<keyword>oral dose</keyword>
</DOC>